What to Do If You Take Too Much Wegovy

What clinical evidence tells us about semaglutide overdose

The Wegovy SmPC documents overdose experience from the STEP clinical trial programme, where some participants received doses above the licensed 2.4 mg maintenance level. The predominant effects recorded were nausea and vomiting, both of which are extensions of semaglutide's normal pharmacological action — the drug slows gastric emptying and acts on appetite centres in the brain, so if you are concerned about too much Wegovy and what it does to the body, those amplified effects are exactly what the evidence describes. Hypoglycaemia was also reported, particularly when semaglutide was used alongside other medicines that lower blood sugar, though Wegovy alone carries a lower hypoglycaemia risk than insulin-based treatments.

There is no specific antidote for a semaglutide overdose. Treatment is supportive: managing symptoms, maintaining hydration, and monitoring blood sugar if relevant. That is why the guidance (including from the NHS semaglutide medicines page) routes people to NHS 111 or a healthcare professional rather than suggesting anything you can do alone at home. The drug's half-life is approximately one week, which means its effects persist well beyond a single injection; getting professional input early matters more than waiting to see whether symptoms resolve.

One misconception worth naming here: some people assume that because nausea is a listed side effect at normal doses, feeling sick after a possible overdose is just normal and will pass. It very well might, but the severity and duration are the signal to act on, not the presence of nausea alone. If you want to understand what happens if you take too much semaglutide, including when vomiting, faintness, or confusion cross the threshold that warrants escalating to emergency care, that guidance sets it out clearly.

How an overdose actually happens with a once-weekly pen

Wegovy comes as a pre-filled, single-use injection pen, and the dose is set by the pen itself rather than measured by the user. That design reduces errors significantly, but it does not eliminate them. The situations our prescribers hear about most often are: injecting again too soon because someone forgot they had already done it that week; accidentally using a pen from the next strength up (for example, picking up the 1 mg pen when you were due a 0.5 mg dose); or double-pressing the pen on the same injection and assuming the dose was not delivered.

The weekly schedule is strict, seven full days between injections. If you are unsure whether you injected this week, do not inject again until you have spoken to your prescriber or called 111. A missed dose is far less risky than a double dose; the Wegovy treatment overview covers the missed-dose rules in more detail, and the Patient Information Leaflet in your pack is the authoritative reference. Storage confusion can also play a role: Wegovy must be refrigerated between 2°C and 8°C, and a pen that has been left at room temperature for longer than the window stated in the leaflet should not be used, which occasionally leads someone to attempt a second injection with a different pen they believe is the valid one.

If you are uncertain which pen or strength you are on, that question is worth raising before your next dose, not after. You can reach the nume support team seven days a week if you are a current patient.

What to do, step by step, if you think you have taken too much

First: do not panic, but do act. The steps below reflect NHS and SmPC guidance for this situation.

If you feel well or only mildly unwell, call NHS 111 and explain you may have taken an extra dose of your weight-loss injection (semaglutide / Wegovy). They will triage you and advise whether you need to be seen. If you are a nume patient, you can also contact our prescribing team directly through the support page, priority aftercare is part of the service, seven days a week.

If symptoms are severe (persistent uncontrollable vomiting, extreme dizziness, feeling faint, confusion, or loss of consciousness) call 999 or get to A&E. Tell the clinical team the medicine name (semaglutide), the brand (Wegovy), the strength of the pen you used, and when you last injected. Bring the pen or its packaging if you can.

Afterwards, report the experience through the MHRA Yellow Card scheme. Patient reports genuinely inform ongoing safety monitoring for medicines like Wegovy, which still carries a Black Triangle (▼) status indicating it is subject to additional MHRA scrutiny. Your report counts.

The question of what comes next (whether to continue treatment, delay your next injection, or adjust your dose) is a clinical one. Your prescriber should know what happened before your next scheduled injection. If you are thinking about semaglutide for weight management and have not yet started, this is also useful context for why clinical supervision matters throughout the process, not just at the start.

Staying safe on Wegovy going forward

Most overdose situations are accidental and, with medical support, manageable. The more useful question after the immediate situation is resolved is: how do we stop this happening again? A few practical steps make a real difference. Keep a simple record (a note on your phone, a calendar reminder) of the day you inject each week. Some people use the same day every week as an anchor (Sunday evenings, for instance) to make the rhythm automatic. Never keep more than one strength of pen in the same location without clear labelling.

If nausea has been severe enough to make you question whether you can continue treatment, that is worth discussing with your prescriber before your next dose rather than after it. Slowing the dose-escalation schedule is a recognised option; you do not have to press through to the next strength on a fixed timetable if your body is still adjusting. The prescriber reviews your case before every dose increase, that review exists precisely to catch these situations.

Understanding the full side-effect profile of semaglutide, including the dedicated guidance on whether you can take too much semaglutide and what that means in practice, is part of treatment literacy. The NHS semaglutide page lists the recognised adverse effects and is kept current, bookmark it as your reference. And if you are at an earlier stage and still weighing up whether this treatment is right for you, our prescribers are the right starting point: you can check your eligibility through a free consultation, with no obligation.